Loading
A method that reads whether a breast cancer still carries the oestrogen receptor from the DNA in a blood sample, when there is enough tumour DNA there.
Griffin profiles nucleosome protection and accessibility from cell-free DNA at as low as 0.1x whole-genome coverage, with a GC correction tailored to fragment size. It predicted oestrogen receptor subtype in 139 patients with metastatic breast cancer with at least 5 per cent detectable ctDNA, with an area under the curve of 0.89, and 0.96 in independent cohorts.
The phenotype of advanced breast cancer, not only its mutations, can be read from blood. The method needs percent-level tumour DNA, so it does not yet reach residual disease after surgery.
Shares Griffin (nucleosome profiling of cell-free DNA), Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left, Cell-free DNA (cfDNA), Estrogen receptor (ERα).
Shares Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left, Cell-free DNA (cfDNA), Estrogen receptor (ERα), Circulating tumour DNA (ctDNA).
Shares Griffin (nucleosome profiling of cell-free DNA), cfDNA fragmentomics, Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares cfDNA fragmentomics, Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares Griffin (nucleosome profiling of cell-free DNA), Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares cfDNA fragmentomics, Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares cfDNA fragmentomics, Cell-free DNA (cfDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/